Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Holtzman

Showing results (431-440 of 742) with videos related to

Pageof 75
Sort By:
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2002
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's diseaseRonald B DeMattos, Mark A O'dell, Maia Parsadanian, et al.
The Journal of Clinical Investigation|December 20, 2000
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrierM Shibata, S Yamada, S R Kumar, et al.
Science (New York, N.Y.)|May 25, 2013
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"Karthikeyan Veeraraghavalu, Can Zhang, Sean Miller, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2017
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 yearsSuzanne E Schindler, Courtney L Sutphen, Charlotte Teunissen, et al.
Neurobiology of Aging|May 9, 2017
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer diseaseSuzanne E Schindler, Mateusz S Jasielec, Hua Weng, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Research Square|February 17, 2023
ApoE Alzheimer's Disease Aβ-amyloid plaque morphology varies according to APOE isotypeIna Caesar, K Peter R Nilsson, Per Hammarstrom, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2000
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's diseaseD M Holtzman, K R Bales, T Tenkova, et al.
Neurochemistry International|October 2, 2001
Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic miceR B DeMattos, R P Brendza, J E Heuser, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2011
Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell deathPhilip B Verghese, Yo Sasaki, Donghan Yang, et al.
Pageof 75

Showing results (431-440 of 742) with videos related to

Sort By:
Pageof 75
Proceedings of the National Academy of Sciences of the United States of America|July 30, 2002
Clusterin promotes amyloid plaque formation and is critical for neuritic toxicity in a mouse model of Alzheimer's diseaseRonald B DeMattos, Mark A O'dell, Maia Parsadanian, et al.
The Journal of Clinical Investigation|December 20, 2000
Clearance of Alzheimer's amyloid-ss(1-40) peptide from brain by LDL receptor-related protein-1 at the blood-brain barrierM Shibata, S Yamada, S R Kumar, et al.
Science (New York, N.Y.)|May 25, 2013
Comment on "ApoE-directed therapeutics rapidly clear β-amyloid and reverse deficits in AD mouse models"Karthikeyan Veeraraghavalu, Can Zhang, Sean Miller, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|July 16, 2017
Upward drift in cerebrospinal fluid amyloid β 42 assay values for more than 10 yearsSuzanne E Schindler, Courtney L Sutphen, Charlotte Teunissen, et al.
Neurobiology of Aging|May 9, 2017
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer diseaseSuzanne E Schindler, Mateusz S Jasielec, Hua Weng, et al.
JAMA Neurology|November 14, 2012
SOD1 in cerebral spinal fluid as a pharmacodynamic marker for antisense oligonucleotide therapyLeah Winer, Dushyanth Srinivasan, Seung Chun, et al.
Research Square|February 17, 2023
ApoE Alzheimer's Disease Aβ-amyloid plaque morphology varies according to APOE isotypeIna Caesar, K Peter R Nilsson, Per Hammarstrom, et al.
Proceedings of the National Academy of Sciences of the United States of America|March 1, 2000
Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's diseaseD M Holtzman, K R Bales, T Tenkova, et al.
Neurochemistry International|October 2, 2001
Purification and characterization of astrocyte-secreted apolipoprotein E and J-containing lipoproteins from wild-type and human apoE transgenic miceR B DeMattos, R P Brendza, J E Heuser, et al.
Proceedings of the National Academy of Sciences of the United States of America|November 8, 2011
Nicotinamide mononucleotide adenylyl transferase 1 protects against acute neurodegeneration in developing CNS by inhibiting excitotoxic-necrotic cell deathPhilip B Verghese, Yo Sasaki, Donghan Yang, et al.
Pageof 75